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ABSTRACT
Malignant glioma is a devastating disease affecting both adults and children with 
limited treatment strategies. Pre-clinical animal studies are critical to the development 
and planning of novel treatment designs for human clinical trials. Topoisomerases has 
been a target of interest in the treatment of high grade gliomas, such as glioblastoma, 
in the past years. Here we assess pre-clinical glioma literature with the aim to identify 
predictive variables that favour treatment outcomes from topoisomerase inhibition. 
Data was extracted from 90 experimental comparisons, this was divided based on 
available survival (n = 61) and tumor volume (n = 29) data. The meta-analysis 
revealed that the overall effect of topoisomerase inhibition prolonged survival by a 
factor of 1.33 (95% CI: 1.23–1.43) and reduced tumor growth by a factor of 3.21 
(95% CI: 1.99–5.88), with considerable between-study heterogeneity. Multivariable 
meta-regression identified glioma model, type of control, route of drug administration 
and drug of choice to be predictive of improved survival outcome. Publication bias 
assessment by contour-enhanced funnel plots, Egger’s regression test and trim and 
fill analysis showed evidence of publication bias in all studies. This study identified 
multiple study design factors that should be taken into consideration to improve the 
translation of pre-clinical investigation of topoisomerase inhibition into clinical use.
www.impactjournals.com/oncotarget/              Oncotarget, 2018, Vol. 9, (No. 13), pp: 11387-11401
INTRODUCTION
Glioblastoma (GBM) is the most common 
malignant brain tumor with an incidence rate of 3.20 
per 100,000 population [1]. GBM increases in incidence 
from the age of 30 years and reaching its peak at 75 to 
84 years old, with a median age of 65 years old [1–5]. 
The addition of temozolomide (TMZ) to surgical resection 
and radiotherapy represented the last significant advance 
in GBM management [6]. However, median survival 
remains at less than 15 months and TMZ resistance has 
since been reported in a proportion of tumors in which the 
O6-methylguanine methyltransferase (MGMT) promoter is 
not methylated [7–11]. In the past 40 years, only a handful 
of drugs have been approved for the treatment of GBM in 
the USA, including temozolomide (2005), bevacizumab 
(2009), carmustine (1996) and lomustine (1976). Overall 
there have been no major advances in chemotherapy for 
GBM in the last decade and, consequently, there is an 
urgent need for new treatments. 
Pre-clinical animal studies form an important stage in 
the development and planning of new treatment designs for 
human clinical trials. Systematic review and meta-analysis 
is a powerful tool for the assessment of any treatment and 
                                                       Meta-Analysis
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is considered to be the highest level of clinical evidence 
by many regulatory bodies. Although systematic review 
and meta-analyses of clinical trials are widely reported, 
until recently there has been a relative paucity concerning 
pre-clinical literature. Groups such as the Collaborative 
Approach to Meta-Analysis and Review of Animal 
Data from Experimental Studies (CAMARADES) have 
undertaken systematic review and meta-analysis across a 
range of pre-clinical disease groups which have illustrated 
several important themes relevant to the design and 
interpretation of animal experiments [12, 13].
Previous systematic reviews of glioma model 
treatments have assessed the efficacy of BCNU/CCNU 
[14], temozolomide [15] and gene therapies [16]. In 
these reviews, particularly in relation to chemotherapies, 
results were overall concordant with human trials, 
although the underlying data were limited in quality and 
design. Several factors were found to be associated with 
observed treatment efficacy including factors relating to 
the reporting of measures to address potential risks of bias 
such as randomization and blinding; and those relating to 
study design, in particular the tumor models used. 
Tumor Suppressor Protein 53 (TP53) is highly 
associated with the regulation of topoisomerase I and 
II activity [17–19]. Mutations in the TP53 gene has 
been found to upregulate topoisomerase II expression 
while leaving topoisomerase I expression unaffected 
[18, 20]. Topoisomerase I and II enzymes are essential 
in the uncoiling of supercoiled DNA to promote DNA 
metabolic processes. Topoisomerase I catalyse single-
strand breaks that allows DNA transcription needed 
for protein synthesis, while Topoisomerase II catalyses 
the double strand breaks important for chromosome 
condensation. Inhibition of topoisomerases lead to the 
increased formation of stable topoisomerase-cleaved 
DNA breaks which eventually lead to cell death [21, 
22]. Topoisomerase inhibition is an established strategy 
in oncology, and has been a target of interest in a range 
of different cancer types including glioma. TP53 
mutations are present in the majority of primary GBMs 
and may contribute to tumorigenesis [23–25]. In the last 
5 years, Phase I and II clinical trials evaluating the use 
of topoisomerase inhibitors in combination with other 
chemotherapeutic drugs to treat GBM have shown variable 
results [26–33]. In 2013, a meta-analysis performed by 
Leonard and Wolff [34] of data from phase I-III clinical 
trials from 1976 to 2011 (including 44,850 patients from 
624 publications) examined the treatment efficacy of four 
topoisomerase inhibitors (topotecan, irinotecan, etoposide 
and teniposide). Of these, etoposide appeared to confer the 
greatest advantage in terms of increase in median survival, 
while others showed either no significant improvement or 
worsened outcome. 
This variability in effects observed in clinical trials 
suggests that topoisomerase inhibition may have a role in 
treatment of glioma if the optimal conditions for efficacy 
(patient selection, timing of treatment, etc.) could be 
identified. This contrasts with the pre-clinical literature 
where the subjective impression is one of consistent 
efficacy. Here we describe a systematic review and meta-
analysis of topoisomerase inhibition in pre-clinical GBM 
studies, with the aim of summarising the overall efficacy 
of topoisomerase inhibition in this population and whether 
differences in efficacy exist between different drugs and 
different tumour models. Furthermore, we appraise the 
quality of these studies and search for evidence of bias; as 
well as describing the variation in and impact of different 
study design parameters on outcome. Finally, we aim to 
appraise the construct validity of the models used.
RESULTS 
After searching PubMed, Medline and EMBASE, 
547 publications were identified with 76 publications 
satisfying the inclusion criteria (Figure 1). We excluded 
one study that used bioluminescent imaging to assess 
for change in tumor volume, as there were no direct 
measurements of tumor volume [35]. Other reasons 
for exclusion were missing or unreported data (n = 5), 
no appropriate control used for the study (n = 11), no 
measure of the variance of the volume data (n = 2) or the 
tumor volumes not reported (n = 2), no quantitative data 
reported for the outcome measure (n = 1), no individual 
drug treatment results reported (n = 2) and the drug being 
assessed in the study is not included in the list of drugs 
specified in the protocol (n = 1).
Following these exclusions, 52 publications 
remained reporting 61 experimental comparisons 
assessing animal median survival (MSR) and 29 assessing 
tumor volume (TVR) data; using a total of 1,611 animals. 
The details of the included studies are presented in 
Supplementary Table 1. 
Of the 90 comparisons, mice were the most 
commonly used species for assessing both survival (n 
= 35) and tumor volume reduction (n = 20). Mice and 
rats were the only species of animal used. Comorbid 
animals were commonly used. Athymic animal models 
were most commonly observed in studies assessing 
survival (n = 26) and in studies assessing tumor volume 
(n = 20). Other comorbidities observed in the survival 
studies were RAG2-M (n = 2) and SCID (n = 2), which 
are both immunocompromised models. SCID animals 
were reported in two out of 29 tumor volume reduction 
experimental comparisons. Survival studies included 56 
intracranial and five subcutaneous animal models, while 
tumor volume reduction studies included 11 intracranial 
and 18 subcutaneous animal models. 
The most frequently used cell line was U87 in both 
survival (n = 14) and volume studies (n = 16). Other 
glioma models more commonly observed were U251 
(n = 7), 9L (n = 8), BT4Ca (n = 5), GBM (n = 7), and 101/8 
(n = 6). Aside from one study which used a patient-derived 
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GBM xenograft model [36], none of the studies screened 
for TP53 mutation (Table 1). The majority of survival 
studies used xenograft models (n = 57), and six of the 
seven experiments that used ‘GBM’ models were serially 
passaged subcutaneous patient-derived xenografts. Most 
tumor models developed were orthotopic (n = 67).
Experiments most commonly used doxorubicin 
(n = 49), followed by irinotecan (n = 25), etoposide 
(n = 7), topotecan (n = 6), and epirubicin (n = 3). The most 
frequently used route of drug delivery were intravenous 
(n = 48), intracranial (n = 21) and intraperitoneal (n = 15) 
administration.
Study quality
Study quality was assessed in all 90 comparisons 
included using a predefined 12-item checklist 
(Supplementary Table 2). The study quality was modest, 
the median number of checklist items scored 6 out of 
12 (IQR – 5–7, range 3–9). Ninety-six percent of the 
comparisons included in the systematic review were 
published in a peer-reviewed journal, 56% reported 
random allocation to treatment groups, 10% blinded the 
assessment of outcome measures, none reported sample 
size calculation, 88% reported compliance with animal 
welfare regulations, 34% stated a potential conflict 
of interest, 26% published “take rates”, 13% reported 
reasons for exclusions, 98% had a consistent site of 
tumor implantation, 87% reported a standard number 
of implanted cells in all the animals, 23% justified drug 
action and 62% justified the use of carriers. 
Meta-analysis
In the 90 comparisons included in the systematic 
review, 18 different glioma models were reported 
Figure 1: Study selection summary. Three public databases were searched for keyword of interest. This returned 547 publications, 
after screening using our inclusion criteria we were left with 38 publications included in the meta-analysis.
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(Supplementary Table 1). However, previous meta-
analyses in this field have suggested a substantial 
degree of covariance between study design parameters, 
particularly the choice of tumor model [15, 16]. To 
limit this covariance, we proceeded to meta-analyse 
studies reporting experiments using glioma models 
which had been used in five or more studies reporting 
the corresponding outcome measure. This involved 47 
survival and 16 tumor volume experimental comparisons 
using a total of 1,192 animals (Figure 2).
Overall, animals bearing gliomas treated with a 
topoisomerase inhibitor survived 1.32 times (95% CI: 1.23 
– 1.43) longer than control animals, substantial between-
study heterogeneity was observed (F = 7.1, p < 0.001, I2 
= 92.2%). On the other hand, topoisomerase inhibition 
reduced tumor growth by 69% (TVR response ratio: 
3.2; 95% CI: 1.99 – 5.18) compared to control animals, 
substantial between-study heterogeneity was also observed 
in this dataset (F = 4.78, p < 0.001, I2 = 95.5%).
Meta-regression
Heterogeneity was high in both datasets, warranting 
further analysis to identify study quality or design items 
associated with treatment efficacy. As specified in our 
protocol, we used a multivariable meta-regression, 
designed to identify and account for covariance between 
study characteristics which is common in heterogeneous 
datasets. In this instance, we suspected glioma model 
selection to be a frequent confounder in univariable 
analyses.
We initially performed univariable meta-regression 
to assess the impact of study characteristics on both 
survival and tumor volume. Variables tested included 
the glioma model, animal species, site of tumor cell 
implantation, drug used, dosage, type of control used, 
route of drug delivery, frequency of drug administration, 
randomisation, blinding of outcome assessment and 
quality score. We deemed the data sufficient to proceed 
to multivariable meta-regression with the survival dataset 
(47 comparisons) but not the tumor volume dataset (18 
comparisons).
For the multivariable meta-regression model, based 
on our previous experience, we allowed inclusion of one 
variable for every ten comparisons – thereby permitting 
input of five predictors. We selected these variables a 
priori to be glioma model, site of implantation, drug used, 
route of delivery, quality score and type of control used for 
the experiment. However, because majority of the tumors 
were orthotopic (n = 44/47) we did not include site of 
implantation, instead we included the variable which had 
returned the largest F-value in the univariable analysis, 
that being the nature of the control used. Following the 
meta-regression, each predictor was tested post-hoc 
with a Wald test – with a significant result implying an 
independent predictive value of the variable of interest.
Our analysis of interest was the multivariable model; 
we report these data first. Where this was not possible, for 
remaining predictors in survival dataset and for the tumor 
volume dataset, we report results from the univariable 
meta-regression.
Survival dataset
The multivariable meta-regression model was 
significantly associated with median survival outcome, 
suggesting a predictive value of at least one variable 
offered (F = 6.08, p < 0.0001), and residual I2 of 74.24%. 
When tested with a Wald test, 4 of 5 variables offered to 
the model (glioma model, drug, type of control, and route 
of drug delivery) were independently associated with 
heterogeneity in the survival dataset (Table 2).
All 4 drugs used appeared to be associated with 
treatment efficacy (Figure 3A), with the most commonly 
used drugs (doxorubicin and irinotecan) associated with 
similar outcomes (MSR: 1.29, 95% CI 1.17–1.43 and 
1.38, 1.16–1.65, respectively). Epirubicin, used in only 2 
experiments, was associated with greater efficacy (1.78, 
95% CI 1.19–2.68). The choice of drug was independently 
predictive of treatment outcome in the multivariable 
model (F = 3.74, p < 0.05), although not in the univariable 
model (F = 1.14, p > 0.0042). The route of drug delivery 
was associated with survival outcome in the multivariable 
model (F = 8.61, p < 0.05, Figure 3B), with intracranial 
treatment appearing to be associated with greater efficacy 
than systemic routes. There was no association seen on 
univariable analysis (F = 3.92, p > 0.0042). Drug dose 
for doxorubicin (F = 0.01, p > 0.0042) and irinotecan (F 
Table 1: TP53 mutation status of glioma models
Cell line group TP53 mutation status
U87 Wildtype [52]
U251 Mutant [53]
GBM SJ – GBM2 – mutant [36]
BT4Ca unknown
9L Mutant [54]
101/8 unknown
Summary of TP53 mutation status for glioma models included in this meta-analysis.
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Figure 2: Meta-analysis of included studies based on outcome measure. (A) Meta-analysis of studies assessing animal survival. 
(B) Meta-analysis of experimental comparisons assessing tumor volume reduction. The grey line represents neutral effect. The x-axis is 
shown in log scale.
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= 0.7, p > 0.0042) was not significantly associated to an 
improved survival outcome in the univariable analysis. 
Drug dose for epirubicin and topotecan were not assessed 
due to low number included in the meta-analysis. The type 
of control, included into the multivariable analysis because 
of a large F-value on univariable analysis (F = 9.94, p < 
0.0042), was also predictive of outcome on multivariable 
meta-regression (F = 3.85, p < 0.05). Studies where the 
control was untreated or given a carrier were associated 
with greater efficacy than those controlled with vehicle or 
saline (Figure 3C).
All 6 glioma models used in survival experiments 
were associated with treatment efficacy (Figure 3D). The 
choice of glioma model was associated with outcome 
heterogeneity on multivariable meta-regression (F = 
6.08, p < 0.05), with human GBM (1.58, 1.22–2.07) 
and rat 101/8 (1.63, 1.34–1.97) cell lines associated 
with greater efficacy than the most frequently reported 
U87 cell line (1.14, 0.90–1.43). Tumor model selection 
was not associated with heterogeneity on univariable 
meta-regression (F = 3.08, p > 0.0042). There were no 
associations between total study quality score and survival 
outcome on either multivariable (F = 0.91, p > 0.05) or 
univariable (F = 0.18, p > 0.0042) analysis.
The remaining variables were tested on univariable 
meta-regression only (Table 3, Figure 4). There were no 
associations between survival outcome and frequency of 
drug administration (F = 1.68, p > 0.0042), site of tumor 
implantation (F = 2.32, p > 0.0042), species (F = 1.68, p 
> 0.0042), comorbidity (1.14, p > 0.0042), the reporting 
of randomised group allocation (F = 0.79, p > 0.0042) or 
blinded assessment of outcome (F = 0.79, p > 0.0042). 
Tumor volume dataset
As there were only 16 experiments included in 
this meta-analysis, we did not apply multivariate meta-
regression. All 16 experiments used a U87 glioma model 
Table 2: Multivariable meta-regression
Variables F p
Model 6.08 0.0005*
Type of control 3.85 0.0185*
Route of drug delivery 8.61 0.001*
Drug 3.74 0.0207*
Quality score 0.91 0.3482
Multivariable meta-regression of predictors identified a priori.
Legend: *p-value < 0.05.
Figure 3: Multivariable meta-regression based on survival outcome. Forest plots of (A) choice of drug, (B) route of drug 
delivery, (C) type of control and, (D) choice of glioma model for the study. Median survival ratio was calculated by dividing the mean 
outcome of the treatment groups by the mean outcome of the control group. The solid grey line represents neutral effect. The x-axis is 
shown in log-scale.
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reported and therefore we could not apply glioma model 
to a univariable meta-regression. Similarly, the majority 
of studies used mice (13/16) and athymic animals 
(14/16), and all were not blinded. Consequently, we 
did not test species, comorbidity or blinded assessment 
of outcome. None of the remaining variables, when 
applied to univariable meta-regression (Table 3, Figure 
5), were found to be predictive of volume outcome, 
including drug (F = 1.05, p > 0.0056), doxorubicin dose 
(F = 0.24, p > 0.0056), irinotecan dose (F = 0.04, p > 
0.0056), route of delivery (F = 1.17, p > 0.0056), type 
of control (F = 0.29, p > 0.0056), frequency of drug 
administration (F = 0.21, p > 0.0056), site of tumor 
implantation (F = 2.47, p > 0.0056), randomised group 
allocation (F = 0.06, p > 0.0056) and quality score (F = 
0.81, p > 0.0056). 
Table 3: Univariable meta-regression
Survival Tumor volume
Variables F p F p
Animal species 1.68 0.2011 − −
Model 3.05 0.0198 na na
Comorbidity 1.14 0.3526 − −
Site of tumor implantation 2.32 0.1349 2.47 0.1386
Drug 1.14 0.3448 1.05 0.405
Route of drug delivery 3.92 0.0271 1.17 0.3601
Type of control 9.94 <0.0001* 0.29 0.8779
Frequency of administration 1.07 0.3518 0.21 0.8168
Randomisation 0.79 0.3801 0.06 0.8146
Blinded outcome assessment 0.79 0.3785 na na
Quality score 0.18 0.671 0.81 0.691
Comparison of univariable meta-regression for survival and tumor volume experimental comparisons.
Legend: *p-value < 0.05; na - not applicable.
Figure 4: Univariable meta-regression based on survival outcome. Forest plots of (A) frequency of drug administration, (B) 
tumor site implantation, (C) animal species, (D) comorbidity, (E) randomisation, and (F) blinding of outcome assessment. The solid grey 
line represents neutral effect. The x-axis is shown in log-scale.
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Post-hoc assessment of drug carriers
Two of the significant results from the two analyses 
pertained to drug delivery – by way of route of delivery 
directly and indirectly in the way of the type of control 
used. We have observed variance in the use of drug carriers 
already and it is possible that the use and choice of carriers 
could affect both of these significant results. As such, we 
thought it important to describe the frequency of carrier 
use (Supplementary Table 3), and have subsequently 
included this stratification post-hoc in the univariable 
metaregression. 
Of the 52 publications included in the systematic 
review, 58% (n = 30) used a carrier for drug delivery. The 
most frequently reported carriers were nanoparticles (n 
= 8) and liposomes (n = 7) as drug carriers all of which 
were administer intravenously except for one study using 
nanoparticles that administered via intraperitoneal route. 
Other carriers observed were polymers (n = 6), drug 
eluting beads (n = 3), nanoliposomes (n = 2), albumin 
(n = 1), micelles (n = 1), microbubbles (n = 1), and 
microspheres (n = 1). Of the 38 publications included in 
the meta-analysis, 25 used a carrier intended to enhance 
drug delivery into the brain. The choice of carrier was not 
associated with heterogeneity in the survival (F = 2.04, 
p = 0.0824) or volume (F = 0.95, p = 0.472) datasets on 
univariable meta-regression (Figure 6).
Publication bias
Taking all studies included in the systematic review, 
we found evidence of publication bias in both datasets. 
For the survival dataset, publication bias was observed by 
means of an asymmetric funnel plot (Figure 7A), and a 
significantly positive intercept in the Egger’s regression 
test (B = 11.24, t = 8.67, p < 0.001, Figure 7B). We 
observed dramatic funnel plot asymmetry in the volume 
dataset (Figure 7C), although Egger’s regression test did 
not show a significantly positive intercept (B = 0.377, 
t = 0.151, p > 0.05, Figure 7D). Trim and Fill analysis 
suggested the presence of 14 ‘missing’ studies in the tumor 
volume dataset (Figure 7C): addition of the ‘missing’ 
studies dramatically reduced overall efficacy from 2.35 
to 1.35. We applied a contour overlay to the funnel plot 
(Figure 7C) to help identify the cause of funnel plot 
asymmetry [37]. In this case, the imputed ‘missing’ tumor 
Figure 5: Univariable meta-regression based on tumour volume reduction. Forest plots of (A) drug of choice, (B) route of 
administration, (C) type of carrier, (D) frequency of administration, (E) site of tumor implantation, and (F) randomisation. The solid grey 
line represents neutral effect. The x-axis is shown in log-scale.
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volume studies are equally distributed between the areas 
of high and non-statistical significance. 
DISCUSSION
In this study, we report the efficacy of five different 
drugs - doxorubicin, epirubicin, etoposide, irinotecan 
and topotecan – in pre-clinical glioma models. Fifty-two 
publications (90 comparisons) satisfied our inclusion 
criteria. Of these, 38 publications with 63 experimental 
comparisons consisting of 1,192 animals for treatment 
efficacy was used for the meta-analysis. Study design was 
heterogeneous and the risk of bias was high.
Nonetheless, we observed that efficacy estimates 
favoured treatment in all drugs in both survival and 
tumor volume data. We have applied a multivariable 
meta-regression which suggests that glioma model, drug 
choice, route of drug delivery and type of control are each 
independently associated with survival outcome in this 
preclinical setting. 
Validity of statistical approach
In previous reviews of the glioma literature [14–
16], a large number of significant results on stratified 
meta-analysis and a particularly large range of efficacies 
observed across a number of glioma models has generated 
suspicion of collinearity and, as such, rendered results 
difficult to interpret.
We therefore devised two strategies to counter this: 
firstly, to exclude infrequently reported glioma models 
(those reported in fewer than five experiments), and 
secondly to apply multivariable meta-regression to the 
remaining data following a standard (univariable) meta-
regression. The univariable meta-regression returned 
fewer significant findings than previous stratified meta-
analyses in glioma studies, probably because meta-
regression is more conservative than stratified meta-
analysis [38, 39]; and because we included fewer studies. 
Based on the multivariable meta-regression analysis, four 
variables were independently associated with survival 
heterogeneity. Three of these, namely glioma model, 
drug and route of drug delivery were nonsignificant on 
univariable meta-regression. The revelation of these 
associations on multivariable modelling confirms the 
presence of collinearity in this data as suspected, and thus 
validates multivariable modelling in this context. 
We suggested that the selection of carrier may have had 
confounded analyses of route of delivery and control used, 
both of which returned significant results meta-regression, 
and on this basis, we felt it appropriate to include carrier 
in univariable meta-regression post hoc. While this result 
was non-significant, we did not include in a multivariable 
model and so it remains possible that a confounding effect 
of drug carriers may exist. We observed no significant 
associations on the univariable analysis of the tumor volume 
dataset, and this is likely a manifestation of a large degree of 
heterogeneity, collinearity and small sample size.
Impact of factors relating to study quality
On further inspection of the included studies we 
found a large range of experimental design, relating 
to both design parameters and measures to reduce the 
risk of bias. Randomisation and blinded assessment of 
outcome are important measures of overall study quality 
and inflated treatment efficacy in the context of a lack 
thereof is a phenomenon well-described in the pre-clinical 
neurosciences literature [40] and in previous glioma 
studies [15, 16]. Infrequent reporting of randomization 
and blinding in this dataset is consistent with other 
studies although we have not observed an association 
with experimental outcome. This may be because of 
collinearity or small sample size, and might be revealed in 
a larger multivariable meta-regression of glioma studies.
Furthermore, we have found evidence of publication 
bias in both datasets by way of asymmetrical Funnel 
plots and a positive Egger’s regression intercept in the 
survival dataset and ‘missing studies’ found in Trim and 
Fill analysis of the tumor volume dataset. These suggest 
that there is a relative lack of small, inefficacious studies 
that are not reported for several reasons [41] and resulting 
in a consequent inflation of efficacy perceived both in 
subjective impressions of the literature and in this meta-
Figure 6: Post-hoc univariable meta-regression analysis of choice of carriers. Post-hoc univariable analysis of carriers used 
in studies assessing (A) survival and (B) tumor volume reduction.
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analysis. Contour enhancement of the funnel plot suggests 
that the asymmetry observed in the tumor volume dataset 
may also be due to other confounding factors rather than 
publication bias alone.
Factors relating to study design
Animal experiments may often be viewed as a 
stepping stone from bench to bedside, given the innate 
similarities between both hosts and their diseases – 
in physiological and genetic terms. Unfortunately, 
animal models have several key features that, although 
not preclusive of their value in research, render them 
imperfect.
Animal experiments are often designed to minimize 
variables and thus tend to report the use of genetically 
similar individuals seeded with tumors derived from a 
single cell line. Immortalized cell lines used to produce 
xenograft models are well established and easy to cultivate, 
although have several key limitations. An example is the 
most commonly used glioma xenograft – U87 – which has 
been observed to have a distinct DNA profile and grow 
in a pattern not typical of a human GBM [42–44]. They 
are genetically homogenous and behave predictably – thus 
lacking heterogeneity observed in GBM patients. Pooling 
of studies in meta-analysis provides a way to simulate 
this heterogeneity and retest a treatment in this context. 
However, its value is dependent on the underpinning 
data – in terms of quality and the experiment’s ability to 
replicate the biology and heterogeneity of human disease. 
An example of note in this context is the TP53 status of 
tumour model used in the studies in this analysis. Of the 
six GBM models found in 70 experimental comparisons 
included in the meta-analysis, four have known TP53 
mutation status but only one study screened for this. 
Based on trend, better response can be observed on TP53 
Figure 7: Publication bias. Funnel plots and Egger’s regression publication bias plot for all studies included in the systematic review 
for both (A and B) survival and (C and D) tumor volume datasets. Survival studies show significant publication bias (p < 0.001) as shown 
by the asymmetry in (A) and by means of a positive intercept (11.24) in (B). For the tumor volume studies, publication bias was observed 
by means of funnel plot asymmetry observed in (C). Trim and fill imputed 14 ‘missing’ studies (red dots) thus reducing overall efficacy 
estimate in (C). Egger’s regression analysis of the tumor volume dataset did not return a significantly positive intercept (D). Funnel plots 
show the effect size (x-axis) against study precision (y-axis). Egger’s regression publication bias plot shows the standardised effects size 
(x-axis) against study precision (y-axis). Solid black lines in (A) and (B) represent the level of neutral effect. Funnel plot in (C) is contour-
enhanced. The light grey shading represents area of high statistical significance, while the white area represents the area of non-statistical 
significance. The darker shaded contour line represents the area of associated statistical significance (p = 0.05).
Oncotarget11397www.impactjournals.com/oncotarget
wildtype cell lines (Table 1, Figure 3D). We have shown 
that glioma model selection is one of the most important 
predictors of treatment efficacy; more so than features 
such as drug of choice and several quality parameters. 
A discrepancy we have observed between this meta-
analysis and a similar review of human clinical trials is 
the absence of doxorubicin [34], contrasting with animal 
studies in which it was the most commonly used drug. 
Glioma model selection should be considered very carefully 
in the design phase of future studies to improve translation 
of pre-clinical investigations to human clinical use. 
In this study we have not pursued the effects of the 
large range of dosing schedules used. Our primary intention 
was to review the overall efficacy of topoisomerase 
inhibitors rather than to tease out the intricacies of dose 
scheduling. Furthermore, to do this would require a 
larger dataset to permit analysis of timing and duration of 
treatment, dosage, frequency and number of cycles with 
sufficient power. To provide a rough insight we used total 
dose, which was not associated with heterogeneity for 
doxorubicin or irinotecan in either dataset.
Limitations of this review
We believe the conclusions drawn from this study 
are important, however these should be taken with caution 
due to a number of limitations. Although meta-analysis 
is a powerful tool, it comes with its weaknesses. It is at 
the mercy of the rigour in which it is undertaken, and we 
have minimised this through transparent reporting and 
prior publication of a protocol. Nonetheless, our search 
terms only included generic drug names (e.g. irinotecan). 
In omitting older synonyms, such as CPT-11, we may 
have missed a small number of older studies. The findings 
of a meta-analysis are only as reliable as the primary 
data included – we found that quality was overall low, 
which should be acknowledged when interpreting the 
results of this study. Meta-analysis is a tool to observe 
associations between study design parameters and 
efficacy; these findings do not imply causality, so should 
only be considered as hypothesis-generating. While we 
have identified and attempted correction for a number of 
confounding factors, further unacknowledged confounders 
could still have distorted our results. An example of this 
is the carrier used for drug delivery, which we did not 
prespecify as a variable of interest in our protocol. When 
a confounding effect subsequently became mechanistically 
and statistically plausible, we were reluctant to include in 
the multivariable model in the interest of preserving the 
integrity of our analysis. Findings and questions arising 
from this review should be answered with prospective, 
high-quality studies. 
CONCLUSIONS
Topoisomerase inhibition has failed to prove 
successful in clinical trials despite apparently consistent 
efficacy in preclinical studies. However, a number of 
concerns arise relating to the internal and construct 
validity of the animal literature: the existing literature is 
at high risk of bias, with evidence of augmented perceived 
treatment efficacy, and animal research has limitations 
in the recapitulation of human disease. Nonetheless, 
factors such as glioma model, type of control used, route 
of administration and type of drug used appear to predict 
outcome and must be taken into consideration when 
planning future studies. We believe that further high-
quality, prospective in vivo studies accommodating these 
conclusions would be invaluable in helping to further 
define the role for topoisomerase inhibition in clinical 
GBM.
MATERIALS AND METHODS
Experimental design
We aimed to undertake a systematic review and 
meta-analysis of topoisomerase inhibition in preclinical 
glioma models; outcome measures of interest were 
changes in survival and tumour volume. Furthermore, 
we anticipated significant heterogeneity between 
studies, which we investigated using meta-regression, 
and publication bias, which we have investigated using 
funnel plots, Egger’s regression test and Trim and Fill 
analysis. 
This was conducted as described in a protocol, 
published online on 15 October 2015. Available at http://
www.dcn.ed.ac.uk/camarades/research.html#protocols. 
Sources
A literature search of phase II clinical trials revealed 
that doxorubicin, epirubicin, etoposide, irinotecan and 
topotecan are the most commonly used FDA-approved 
topoisomerase inhibitors for the treatment of GBM. 
In August 2014, we searched PubMed, Medline and 
Embase for the following keywords: (glioblastoma or 
glioblastoma multiforme or GBM or high-grade glioma) 
AND (Doxorubicin OR Epirubicin OR Etoposide OR 
Irinotecan OR Topotecan). The search was limited to in 
vivo studies with predeveloped filters [45, 46], with no 
language or publication date restrictions. The search was 
updated in July 2016.
Inclusion criteria
During the screening process, criteria for inclusion 
required the following information from the studies: (i) 
a topoisomerase inhibitor used as monotherapy, (ii) use 
of an adult high-grade glioma model, (iii) intracranial or 
subcutaneous tumor implantation and (iv) tumor volume 
or median survival reported as the outcome measure. The 
title and abstracts were screened by two of the authors (TJ 
and TH) for inclusion.
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Data extraction
All data extracted were entered into the 
CAMARADES data manager application. Data were 
extracted regarding the publication (author names, year 
of publication, and title), intervention (drug used, dose, 
dose frequency, route of administration, drug delivery 
method, delay to treatment, and time of assessment 
based on day 0 of treatment), animal population (species, 
strain, sex, age, and number of animals per group), tumor 
implantation (cell type used, site of implantation, number 
or volume of cells inoculated and inoculation method 
used) and outcome measures (tumor volume and median 
survival data). All data used in this study is available in 
Supplementary Dataset 1.
The median survival and tumor volume data were 
estimated from graphs using a desktop ruler when these 
were not provided in the text. 
Study quality scoring
A modified 12-item checklist adapted from 
previously published studies was used to assess the quality 
of the studies and determine possible publication bias 
(Supplementary Table 2) [14–16].
Statistical analysis
A summary statistic was initially performed for 
each individual study. For survival data, we used median 
survival ratio as described previously [47] and for tumor 
volume data we used response ratio [48]. Data were then 
normalized via log transformation and pooled using 
DerSimonian and Laird random-effects meta-analysis. We 
weighted survival studies by the number of animals in the 
study as a surrogate marker for inverse variance [47].
We assessed for the presence of heterogeneity using 
the I2 statistic and investigated sources of heterogeneity 
using meta-regression (via the metareg command in 
STATA 12.0). To limit the covariance observed in 
glioma models, we excluded those studies using glioma 
models reported in fewer than five experiments. We then 
performed a univariable meta-regression followed by a 
multivariable meta-regression where sufficient data were 
present; further details are described in the results section. 
Bonferroni correction was applied on the comparisons 
in the univariable meta-regression; critical p-value was 
adjusted to p = 0.0042 for survival data (12 comparisons) 
and p = 0.0056 for volume data (nine comparisons). In 
multivariable meta-regression, critical p-value was set 
at 0.05. Publication bias was assessed using contour-
enhanced funnel plots, Egger’s regression test and ‘Trim 
and Fill’ analysis using ‘foresplot’ and ‘metafor’ R 
packages [37, 49–51]. Contour enhancement of funnel 
plots was performed to help identify cause of funnel plot 
asymmetry [37]. All tests reported are two-sided. 
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